M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies Pharmaceutical TechnologyBioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. M&A / DealsImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Medicare obesity drug pilot extended after insurer pushbackNext: BioAegis and Prenosis partner for inflammatory disease therapies Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
